Drug Profile
Research programme: peptide vaccines - Generex Biotechnology
Alternative Names: Ii-Key-SARS-2 vaccine - EpiVax/Generex Biotechnology; 2019-nCoV vaccine - EpiVax/Generex Biotechnology; SARS-CoV-2 Vaccine - EpiVax/Generex BiotechnologyLatest Information Update: 29 May 2020
Price :
$50
*
At a glance
- Originator Generex Biotechnology Corporation
- Developer EpiVax; Generex Biotechnology Corporation
- Class COVID-19 vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections